The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study

被引：0
|
作者：
Piotr Rutkowski
Elżbieta Bylina
Anna Klimczak
Tomasz Świtaj
Sławomir Falkowski
Jacek Kroc
Iwona Ługowska
Magdalena Brzeskwiniewicz
Wojciech Melerowicz
Czesław Osuch
Ewa Mierzejewska
Kacper Wasielewski
Agnieszka Woźniak
Urszula Grzesiakowska
Zbigniew I Nowecki
Janusz A Siedlecki
Janusz Limon
机构：
[1] Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology,Department of Soft Tissue/Bone Sarcoma and Melanoma
[2] Pfizer Poland,Department of Biology and Genetics
[3] Medical University of Gdansk,Department of General Surgery
[4] GreaterPoland Oncological Center,Department of Biostatistics
[5] Jagiellonian University,Laboratory of Experimental Oncology and Department of General Medical Oncology
[6] Medical Faculty,Department of Radiology
[7] Institute of Mother and Child,Department of Gastrointestinal Tumors
[8] KU Leuven and University Hospital,Department of Molecular Biology
[9] Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology,undefined
[10] Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology,undefined
[11] Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology,undefined
来源：
BMC Cancer | / 12卷
关键词：
Sunitinib; Genotype; GIST; Prognosis; Predictive factors; Arterial hypertension;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
下载
收藏
相关论文
共 50 条
  • [41] Sunitinib - a new approach following failure of imatinib in patients with advanced gastrointestinal stromal tumor
    Debiec-Rychter, Maria
    NATURE CLINICAL PRACTICE ONCOLOGY, 2007, 4 (06): : 342 - 343
  • [42] Surgical treatment of patients (pts) with gastrointestinal stromal tumors (GIST) after imatinib mesylate (IM) therapy.
    Rutkowski, P
    Nowecki, Z
    Nyckowski, P
    Dziewirski, W
    Nasierowska-Guttmejer, A
    Grzesiakowska, U
    Michej, W
    Krawczyk, M
    Ruka, W
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 825S - 825S
  • [43] Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
    Demetri, George D.
    van Oosterom, Allan T.
    Garrett, Christopher R.
    Blackstein, Martin E.
    Shah, Manisha H.
    Verweij, Jaap
    McArthur, Grant
    Judson, Ian R.
    Heinrich, Michael C.
    Morgan, Jeffrey A.
    Desai, Jayesh
    D Fletcher, Christopher
    George, Suzanne
    Bello, Carlo L.
    Huang, Xin
    Baum, Charles M.
    Casali, Paolo G.
    LANCET, 2006, 368 (9544): : 1329 - 1338
  • [44] COST-EFFECTIVENESS OF IMATINIB IN THE TREATMENT OF ADVANCED GASTROINTESTINAL STROMAL TUMORS (GIST): CANADIAN PERSPECTIVE
    El Ouagari, K.
    Huse, D. M.
    ANNALS OF ONCOLOGY, 2008, 19 : 227 - 227
  • [45] Cost-effectiveness (CE) of imatinib (IM) in the treatment of advanced gastrointestinal stromal tumors (GIST)
    Huse, Daniel
    Lenhart, Greg
    Feng, Weiwei
    Blanke, Charles
    Joensuu, Heikki
    Mehren, Margaret V.
    Demetri, George D.
    ANNALS OF ONCOLOGY, 2006, 17 : 162 - 162
  • [46] REAL-LIFE MANAGEMENT OF ADVANCED GASTROINTESTINAL STROMAL TUMORS (GIST) TREATED WITH IMATINIB IN FRANCE
    Bouche, O.
    Le Cesne, A.
    Rios, M.
    Chaigneau, L.
    Bui, B.
    Xavier, P.
    Blay, J.
    ANNALS OF ONCOLOGY, 2012, 23 : 236 - 236
  • [47] Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile?
    Tielen, Ronald
    Verhoef, Cornelis
    van Coevorden, Frits
    Gelderblom, Hans
    Sleijfer, Stefan
    Hartgrink, Henk H.
    Bonenkamp, Johannes J.
    van der Graaf, Winette T.
    de Wilt, Johannes H. W.
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2012, 10
  • [48] Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile?
    Ronald Tielen
    Cornelis Verhoef
    Frits van Coevorden
    Hans Gelderblom
    Stefan Sleijfer
    Henk H Hartgrink
    Johannes J Bonenkamp
    Winette T van der Graaf
    Johannes H W de Wilt
    World Journal of Surgical Oncology, 10
  • [49] Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib
    Nemunaitis, John
    Bauer, Sebastian
    Blay, Jean-Yves
    Choucair, Khalil
    Gelderblom, Hans
    George, Suzanne
    Schoffski, Patrick
    von Mehren, Margaret
    Zalcberg, John
    Achour, Haroun
    Ruiz-Soto, Rodrigo
    Heinrich, Michael C.
    FUTURE ONCOLOGY, 2020, 16 (01) : 4251 - 4264
  • [50] Improved Efficacy of First-Line Imatinib in Advanced Gastrointestinal Stromal Tumors (GIST): The Dutch GIST Registry Data
    Mohammadi, Mahmoud
    IJzerman, Nikki S.
    den Hollander, Dide
    Bleckman, Roos F.
    Oosten, Astrid W.
    Desar, Ingrid M. E.
    Reyners, An K. L.
    Steeghs, Neeltje
    Gelderblom, Hans
    TARGETED ONCOLOGY, 2023, 18 (03) : 415 - 423
12345